Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: New England Journal of Medicine
Authors: Toni K. Choueiri, Robert J. Motzer, Jose A. Karam, Wesley Yip, Cristina Suárez, Dingwei Ye, Zhisong He, Christian Caglevic, Tom Ferguson, Yen-Hwa Chang, Carlos Rojas, Roberto Iacovelli, Yüksel Ürün, Elena Verzoni, Juan Carlos Vázquez Limón, Camillo Porta, Robert G. Uzzo, Jae Lyun Lee, Balaji Venugopal, Rana R. McKay, Hans Hammers, Hideaki Miyake, Jad Chahoud, Hong Liu, Joseph E. Burgents, Manish Sharma, Thomas B. Powles
Institutions: Harvard University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Fudan University Shanghai Cancer Center, Peking University First Hospital, Fundación Arturo López Pérez, Fiona Stanley Hospital, Taipei Veterans General Hospital, Finis Terrae University, Agostino Gemelli University Polyclinic, Ankara University, Fondazione IRCCS Istituto Nazionale dei Tumori, Universidad de Guadalajara, Hospital Civil de Guadalajara, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, University of Bari Aldo Moro, Fox Chase Cancer Center, Asan Medical Center, University of Ulsan, Beatson West of Scotland Cancer Centre, University of Glasgow, University of California San Diego, The University of Texas Southwestern Medical Center, Hamamatsu University School of Medicine, Moffitt Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, National Institute for Health and Care Research, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Merck Sharp and Dohme
OpenAlex ID: W7166878417